Observational Study on Long-Term Safety and Effectiveness of Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma

What this Trial Is About

Researchers are studying lisocabtagene maraleucel liso-cel to understand its long-term safety and effectiveness in treating patients with Mantle Cell Lymphoma MCL who have relapsed or refractory disease. This observational study focuses on patients treated with liso-cel following its approval and commercial release in the United States. The study aims to gather data for up to 15 years after treatment to provide a comprehensive view of patient outcomes. Participants in this study have already received at least one infusion of lisocabtagene maraleucel according to the FDA-approved guidelines and dosage. The study does not involve assigning treatments but rather observes patients who have been treated with liso-cel in routine clinical practice. There are no additional interventions or comparators. During the study, researchers will collect information about adverse events, complete remission rates, overall response rates, progression-free survival, and overall survival for up to 15 years. Participants health will be monitored through routine data collection, without extra procedures or treatments mandated by the study. The long follow-up period allows for detailed assessment of the treatments impact over time.

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting